MDT vs RMD vs BSX Stock Comparison

Medtronic, Resmed and Boston Scientific Prices as of Nov 13, 2026 Peers: Industry group
MDT Medtronic plc
$102.86 +9.2% 1M +7.0% 1Y
Market cap
$132.41B
P/E
15.1x
Revenue (TTM)
$37.10B
Div. yield
0.03%
Medical Devices Healthcare
5 wins
RMD Resmed Inc
$239.53 +1.7% 1M -5.0% 1Y
Market cap
$34.59B
P/E
21.7x
Revenue (TTM)
$5.73B
Div. yield
–
Medical Devices Healthcare
4 wins
BSX Boston Scientific Corp
$44.34 +3.1% 1M -57.8% 1Y
Market cap
$64.09B
P/E
18.3x
Revenue (TTM)
$21.07B
Div. yield
–
Medical Devices Healthcare
2 wins

Head to Head

11 decided of 12

Medtronic leads on 5 of the 12 questions below (Medtronic 5, Resmed 4, Boston Scientific 2). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionMDTRMDBSXLeader
Larger companyMarket capitalisation $132.41B $34.59B $64.09B MDT
Cheaper on earningsLower P/E, profitable companies only 15.1x 21.7x 18.3x MDT
Cheaper on forward earningsLower price / next fiscal year consensus EPS 18.5x 18.5x 14.5x BSX
Faster revenue growthRevenue growth, trailing twelve months +12.8% +9.0% +8.9% MDT
More profitableNet margin, trailing twelve months 23.6% 27.8% 16.6% RMD
Better return on capitalReturn on invested capital 11.7% 22.0% 9.9% RMD
Less leveragedLower net debt / EBITDA 1.2x -0.3x 2.1x RMD
Higher dividend yieldTrailing dividend yield 0.03% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months +7.0% -5.0% -57.8% MDT
Better 5-year returnAnnualised price return, 5 years -2.9%/yr -1.2%/yr +1.1%/yr BSX
Less volatileAnnualised volatility, 1 year 25.6% 31.1% 41.5% MDT
Higher overall scoreMean of the five percentile scores vs peers 63/100 80/100 68/100 RMD

Percentile Scorecard

MDTRMDBSX

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisMDTRMDBSX
Valuation 87 #32 of 243 75 #62 of 243 87 #33 of 243
Growth 35 #149 of 228 60 #92 of 228 68 #73 of 228
Profitability 98 #6 of 222 99 #3 of 222 91 #20 of 222
Financial Health 50 #124 of 248 76 #61 of 248 43 #142 of 248
Shareholder Returns 43 #90 of 158 89 #18 of 158 48 #82 of 158
Overall 63 80 68
  • MDT ranked among 252 companies in Medical Devices and Diagnostics
  • RMD ranked among 252 companies in Medical Devices and Diagnostics
  • BSX ranked among 252 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodMDTRMDBSXSPY
1 month +9.2%+1.7%+3.1% -2.0%
3 months +12.7%+6.7%-14.5% -2.8%
6 months +35.1%+18.6%-15.8% +2.0%
Year to date +7.1%-0.6%-53.5% +10.6%
1 year +7.0%-5.0%-57.8% +12.2%
3 years +41.7%+62.6%-17.9% +68.1%
3 years, per year +12.3%+17.6%-6.4% +18.9%
5 years -13.8%-6.0%+5.4% +61.4%
5 years, per year -2.9%-1.2%+1.1% +10.1%
10 years +25.3%+300.2%+106.2% +248.5%
10 years, per year +2.3%+14.9%+7.5% +13.3%

Risk

MeasureMDTRMDBSXSPY
Volatility, 1Y 25.6%31.1%41.5% 13.6%
Downside volatility, 1Y 22.3%33.9%47.7% 13.9%
Beta vs S&P 500, 1Y 0.140.510.26 1.00
Return / volatility, 1Y 0.27-0.16-1.39 0.90
Max drawdown, 5Y -41.2%-49.8%-61.6% -25.4%
From 52-week high -2.4%-13.2%-57.8% -3.2%
52-week high $105.35$275.96$104.98 $779.14
52-week low $73.75$182.82$41.57 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleMDTRMDBSX
P/E now vs peer median 15.0xmedian 26.5x 21.5xmedian 26.5x 18.3xmedian 26.5x
P/S now vs peer median 3.5xmedian 2.7x 5.9xmedian 2.7x 3.1xmedian 2.7x
EV/EBITDA now vs peer median 9.2xmedian 18.4x 15.8xmedian 18.4x 14.1xmedian 18.4x
P/FCF now vs peer median 10.3xmedian 25.4x 20.9xmedian 25.4x 19.3xmedian 25.4x
P/B now vs peer median 2.6xmedian 2.5x 5.7xmedian 2.5x 2.5xmedian 2.5x
PEG now vs peer median 1.85median 0.98 0.99median 0.98 0.42median 0.98

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsMDTRMDBSX
Revenue $37.10B $5.73B $21.07B
Gross profit $24.23B $3.50B $14.57B
Operating income $11.28B $1.89B $3.93B
Net income $8.81B $1.59B $3.49B
Free cash flow $12.74B $1.61B $3.33B
R&D $4.93B $393.82M $2.16B
EPS (diluted) $6.81 $11.11 $2.41
Cash & equivalents $1.69B $1.01B $609.00M
Total debt $28.15B $409.60M $11.95B
Shares (diluted) 1.29B 143.41M 1.45B
Enterprise value $97.92B $29.03B $59.52B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricMDTRMDBSX
P/E 15.0x 21.5x 18.3x
P/FCF 10.3x 20.9x 19.3x
P/Operating cash flow 10.7x 19.0x 15.2x
P/S 3.5x 5.9x 3.1x
P/B 2.6x 5.7x 2.5x
P/Tangible book 3.2x 6.1x 3.4x
EV/EBITDA 9.2x 15.8x 14.1x
EV/EBIT 13.4x 17.5x 19.2x
EV/Revenue 4.1x 5.8x 3.6x
EV/FCF 11.9x 20.6x 22.7x
EV/Operating cash flow 12.2x 18.7x 17.9x
PEG (3Y EPS CAGR) 1.85 0.99 0.42

Growth

14 metrics
MetricMDTRMDBSX
Revenue growth (1Y) 12.8% 9.0% 8.9%
Revenue CAGR (3Y) 6.7% 9.4% 15.3%
Gross profit growth (1Y) 13.1% 11.0% 9.8%
Gross profit CAGR (3Y) 6.0% 13.2% 15.1%
Operating income growth (1Y) 19.2% 8.5% 13.5%
Operating income CAGR (3Y) 5.7% 18.2% 22.1%
Net income growth (1Y) -17.8% 10.8% 25.5%
Net income CAGR (3Y) -4.4% 20.7% 41.7%
EPS growth (1Y) 24.7% 13.5% 29.2%
EPS CAGR (3Y) 8.1% 21.8% 44.0%
Operating cash flow growth (1Y) -22.3% -6.0% -8.5%
Operating cash flow CAGR (3Y) -6.7% 23.7% 21.6%
Free cash flow growth (1Y) 27.6% -9.0% -12.9%
Free cash flow CAGR (3Y) 6.7% 25.5% 25.2%

Profitability

14 metrics
MetricMDTRMDBSX
Gross margin 65.3% 61.1% 69.1%
EBITDA margin 44.0% 36.4% 25.5%
Operating margin 30.4% 33.0% 18.7%
Pretax margin 29.2% 35.1% 17.3%
Net margin 23.6% 27.8% 16.6%
FCF margin 34.3% 28.1% 15.8%
Operating cash flow margin 33.2% 30.9% 20.1%
Return on equity 17.5% 25.4% 13.7%
Return on assets 9.5% 18.5% 7.7%
Return on invested capital 11.7% 22.0% 9.9%
Return on capital employed 13.9% 26.1% 10.0%
Asset turnover 0.4x 0.7x 0.5x
Cash conversion (OCF / net income) 1.4x 1.1x 1.2x
Stock comp / revenue 2.2% 2.0% 1.5%

Financial Health

11 metrics
MetricMDTRMDBSX
Debt / assets 30.2% 5.0% 26.3%
Debt / equity 0.6x 0.1x 0.5x
Net debt / EBITDA 1.2x -0.3x 2.1x
Debt / FCF 2.2x 0.3x 3.6x
Liabilities / assets 45.5% 27.6% 43.1%
Equity / assets 54.5% 72.4% 56.9%
Interest coverage 8.9x 81.1x 10.5x
Current ratio 2.1x 2.6x 1.4x
Quick ratio 1.3x 1.5x 0.6x
Cash ratio 0.7x 0.8x 0.1x
Altman Z-score 3.32 12.00 3.03

Shareholder Returns

7 metrics
MetricMDTRMDBSX
Dividend yield 2.8% 1.1% –
Net buyback yield -2.6% 4.2% -0.3%
Shareholder yield 0.1% 5.3% -0.3%
Payout ratio (earnings) 41.4% – –
Payout ratio (FCF) 28.7% – –
Dividend growth (1Y) 0.7% – –
Dividend CAGR (3Y) 0.7% – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusMDTRMDBSX
Forward P/E 18.5xFY2026 18.5xFY2027 14.5xFY2026
EPS, next fiscal year $5.57FY2026 $12.92FY2027 $3.06FY2026
EPS growth, next FY +0.7%FY2026 +15.7%FY2027 0.0%FY2026
EPS growth, the year after +7.4% +8.9% +8.2%
Revenue, next fiscal year $39.92BFY2026 $5.99BFY2027 $20.48BFY2026
Revenue growth, next FY +9.8%FY2026 +6.0%FY2027 +2.1%FY2026
Revenue growth, the year after -4.7% -3.8% -4.0%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersMDTRMDBSX
Held by institutions 85.1% 68.7% 90.5%
Institutions holding 2,128 889 1,484
Change in shares held, QoQ -0.2% +3.2% -0.7%
Institutions buying 1,015 404 738
Institutions selling 915 360 612
Buyers to sellers 1.11 1.12 1.21

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

MDTRMDBSX
MDT 1.00 0.50 0.48
RMD 0.50 1.00 0.24
BSX 0.48 0.24 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, MDT, RMD and BSX?

Medtronic (MDT) is the largest by market capitalisation: Medtronic (MDT) $132.41B, Resmed (RMD) $34.59B, Boston Scientific (BSX) $64.09B.

Which stock is cheaper, MDT, RMD and BSX?

Medtronic (MDT) trades on the lowest price-to-earnings ratio (Medtronic (MDT) 15.1x, Resmed (RMD) 21.7x, Boston Scientific (BSX) 18.3x). On next year's consensus earnings, Boston Scientific (BSX) is cheapest (Medtronic (MDT) 18.5x, Resmed (RMD) 18.5x, Boston Scientific (BSX) 14.5x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Medtronic (MDT) grew revenue fastest over the trailing twelve months: Medtronic (MDT) +12.8%, Resmed (RMD) +9.0%, Boston Scientific (BSX) +8.9%.

Which company is more profitable?

Resmed (RMD) has the highest net margin (Medtronic (MDT) 23.6%, Resmed (RMD) 27.8%, Boston Scientific (BSX) 16.6%). On return on invested capital, Resmed (RMD) leads (Medtronic (MDT) 11.7%, Resmed (RMD) 22.0%, Boston Scientific (BSX) 9.9%).

Which stock has performed better?

Over the past year Medtronic (MDT) returned the most: Medtronic (MDT) +7.0%, Resmed (RMD) -5.0%, Boston Scientific (BSX) -57.8%. Over five years, Boston Scientific (BSX) compounded fastest (Medtronic (MDT) -2.9%/yr, Resmed (RMD) -1.2%/yr, Boston Scientific (BSX) +1.1%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Only one of these companies pays a dividend: Medtronic (MDT) 0.03%, Resmed (RMD) 0.00%, Boston Scientific (BSX) 0.00%. Resmed (RMD) and Boston Scientific (BSX) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Medtronic (MDT) has been the steadiest (Medtronic (MDT) 25.6%, Resmed (RMD) 31.1%, Boston Scientific (BSX) 41.5%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, MDT, RMD and BSX?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Medtronic (MDT) leads on 5. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.